You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Database of hazardous chemicals.
Record Information
Version1.0
Creation Date2014-09-11 05:16:04 UTC
Update Date2016-10-28 10:04:10 UTC
Accession NumberCHEM003732
Identification
Common NameFenofibrate
ClassSmall Molecule
DescriptionAn antilipemic agent which reduces both cholesterol and triglycerides in the blood.
Contaminant Sources
  • HMDB Contaminants - Urine
  • STOFF IDENT Compounds
  • Suspected Compounds - Waste Water
  • Suspected Compounds – Schymanski Project
  • T3DB toxins
  • ToxCast & Tox21 Chemicals
Contaminant Type
  • Drug
  • Ester
  • Ether
  • Hypolipidemic Agent
  • Metabolite
  • Organic Compound
  • Organochloride
  • Synthetic Compound
Chemical Structure
Thumb
Synonyms
ValueSource
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl esterChEBI
FinofibrateChEBI
FNFChEBI
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionateChEBI
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionateChEBI
LipantilChEBI
ProcetofenChEBI
TricorChEBI
AntaraKegg
LipofenKegg
TriglideKegg
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoate 1-methylethyl esterGenerator
Finofibric acidGenerator
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionic acidGenerator
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acidGenerator
Fenofibric acidGenerator
AZU, fenofibratHMDB
Abbott brand OF procetofenHMDB
Antara micronized procetofenHMDB
Anto brand OF procetofenHMDB
Apo fenofibrateHMDB
Fenofibrat heumannHMDB
Gen fenofibrateHMDB
Genpharm brand OF procetofenHMDB
Heumann brand OF procetofenHMDB
Heumann, fenofibratHMDB
Hexal brand OF procetofenHMDB
Lichtenstein brand OF procetofenHMDB
LipanthylHMDB
LivesanHMDB
LofibraHMDB
MTW FenofibratHMDB
MTW-FenofibratHMDB
NormalipHMDB
Pharmascience brand OF procetofenHMDB
ProcetofeneHMDB
Stada, fenofibratHMDB
SupralipHMDB
DurafenatHMDB
Apo feno microHMDB
Apo-fenofibrateHMDB
Bouchara brand OF procetofenHMDB
CiLHMDB
FenobetaHMDB
Fenofibrat hexalHMDB
Fenofibrat stadaHMDB
Fenofibrat-ratiopharmHMDB
GNR Pharma brand OF procetofenHMDB
gate Brand OF procetofenHMDB
Gen-fenofibrateHMDB
Knoll brand OF procetofenHMDB
Lipidil terHMDB
MTW Brand OF procetofenHMDB
Micronized procetofen, antaraHMDB
Novartis brand OF procetofenHMDB
Nu fenofibrateHMDB
Procetofen reliant brandHMDB
Q-Pharm brand OF procetofenHMDB
Reliant brand OF procetofenHMDB
Schering plough brand OF procetofenHMDB
Ratiopharm brand OF procetofenHMDB
Apo-feno-microHMDB
Azupharma brand OF procetofenHMDB
Fenofibrat azuHMDB
Fenofibrat abzHMDB
Fenofibrat FPHHMDB
Fenofibrat ratiopharmHMDB
Fénofibrate MSDHMDB
Hexal, fenofibratHMDB
Merck dura brand OF procetofenHMDB
Novo-fenofibrateHMDB
Novopharm brand OF procetofenHMDB
Nu pharm brand OF procetofenHMDB
Nu-fenofibrateHMDB
Nu-pharm brand OF procetofenHMDB
PMS-Fenofibrate microHMDB
PhenofibrateHMDB
Schering-plough brand OF procetofenHMDB
United drug brand OF procetofenHMDB
Betapharm brand OF procetofenHMDB
CT Arzneimittel brand OF procetofenHMDB
CT-Arzneimittel brand OF procetofenHMDB
AbZ brand OF procetofenHMDB
Aliud brand OF procetofenHMDB
Apotex brand OF procetofenHMDB
ControlipHMDB
Debat, fénofibrateHMDB
FenofantonHMDB
Fenofibrat alHMDB
Fournier brand OF procetofenHMDB
Fénofibrate debatHMDB
GNR-Pharma brand OF procetofenHMDB
LiparisonHMDB
LipidilHMDB
Lipidil-terHMDB
Novo fenofibrateHMDB
PMS Fenofibrate microHMDB
Procetofen, antara micronizedHMDB
Q Pharm brand OF procetofenHMDB
SecalipHMDB
Stadapharm brand OF procetofenHMDB
Fenofibrat von CTHMDB
Chemical FormulaC20H21ClO4
Average Molecular Mass360.831 g/mol
Monoisotopic Mass360.113 g/mol
CAS Registry Number49562-28-9
IUPAC Namepropan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Traditional Nameantara
SMILESCC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
InChI IdentifierInChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChI KeyYMTINGFKWWXKFG-UHFFFAOYSA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Aryl-phenylketone
  • Diphenylmethane
  • Phenoxyacetate
  • Phenoxy compound
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Chlorobenzene
  • Halobenzene
  • Aryl chloride
  • Aryl halide
  • Carboxylic acid ester
  • Ketone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Ether
  • Organohalogen compound
  • Organic oxygen compound
  • Carbonyl group
  • Organochloride
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginExogenous
Cellular Locations
  • Cytoplasm
  • Membrane
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateSolid
AppearanceWhite powder.
Experimental Properties
PropertyValue
Melting Point80.5°C
Boiling PointNot Available
Solubility0.25mg/ml at 25°C
Predicted Properties
PropertyValueSource
Water Solubility0.00071 g/LALOGPS
logP4.86ALOGPS
logP5.28ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 ŲChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.13 m³·mol⁻¹ChemAxon
Polarizability38.15 ųChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSsplash10-00dl-6390000000-5464dc4b809f70f9340dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , Positivesplash10-000i-0122900000-4e3cc64221a0b278b61eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0090000000-f4e7816cd30c8701cce3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0029000000-60bbd2de375b9b56ec55View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0190000000-6e83f7c906eaeb363cafView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0019-0930000000-fccf28abf1a426a6949bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-07739caadc1c26a7baaaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-5045a0039b18e3d7dd9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-1900000000-25a145c2138d34aa4b52View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0029000000-a98245ce05ccb6a6707eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0190000000-4e9b3e71fc7960db389eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0019-0930000000-9d3908b5ee8b5f59218dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-1090af5e239a872654d9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-5dcab26837d06f9756f8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-1900000000-2663fed5f3ba78d3c7a5View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0090000000-4933bea6ce44715c6172View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-01qi-0595000000-d3c4c1cce3b5e1fbb33fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-01qi-1594000000-9756f301ee5d44577654View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-000i-3920000000-91103d7fd9d1063bae9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0019-0941000000-27e0cd2c4e952b499a9aView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-03di-0039000000-944af46f336da55a8475View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-001i-2293000000-4801131855d2da97d5eeView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-00ec-5970000000-1378e4f4b3a07ef9697dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-0119000000-2b2235f5a6097ea83d1eView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-053r-1297000000-e56c9f467ebb0930e34aView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-00lr-0970000000-abe9ec8d570cd8856680View in MoNA
Toxicity Profile
Route of ExposureFenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Mechanism of ToxicityFenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
MetabolismRoute of Elimination: Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces. Half Life: 20 hours
Toxicity ValuesLD50=1600 mg/kg (Oral, in mice)
Lethal DoseNot Available
Carcinogenicity (IARC Classification)No indication of carcinogenicity to humans (not listed by IARC).
Uses/SourcesFor use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Minimum Risk LevelNot Available
Health EffectsInvestigated as a teratogen and reproductive hazard.
SymptomsNot Available
TreatmentNot Available
Concentrations
StatusValueUnitSample LocationReference
Not Detected
DrugBank IDDB01039
HMDB IDHMDB0015173
FooDB IDNot Available
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkFenofibrate
Chemspider ID3222
ChEBI ID5001
PubChem Compound ID3339
Kegg Compound IDC07586
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis Reference

Jean-Francois Boyer, “Medicine based on fenofibrate, and a method of preparing it.” U.S. Patent US4800079, issued January, 1988.

MSDSLink
General References
1. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7.
2. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
3. https://www.ncbi.nlm.nih.gov/pubmed/?term=17449930
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=18212815